Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Cytokinetics Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Cytokinetics Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net loss
Non-cash interest expense on liabilities related to revenue participation right purchase agreements
Stock-based compensation expense
Non-cash lease expense
Impairment of right-of-use assets
Depreciation of property and equipment
(Gain) loss on investments, net
Interest receivable and amortization on investments
Non-cash interest expense related to debt
Loss on extinguishment of debt
Loss on inducement of convertible debt
Accounts receivable
Contract assets
Prepaid and other assets
Accounts payable
Accrued and other liabilities
Contract liabilities
Operating lease liabilities
Other non-current liabilities
Deferred revenue
Changes in operating assets and liabilities
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Purchases of investments
Maturities of investments
Sales of investments
Purchases of property and equipment
Sales of property and equipment
Net cash (used in) provided by investing activities
Repayment of finance lease liabilities
Repayment of term loan
Debt extinguishment costs
Repayment of convertible debt
Proceeds from issuance of convertible debt, net
Proceeds from public offerings of common stock, net of discounts, commissions and offering cost
Proceeds from private placement, net
Proceeds from 2022 RPI Transactions, net
Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs
Proceeds from issuance of common stock under equity incentive and stock purchase plans
Taxes paid related to net share settlement of equity awards
Claims settlement under Section 16(b)
Cash settlement of capped call options associated with 2026 Notes
Net proceeds from long-term debt, net of debt discount and issuance costs
Purchase of capped call options associated with convertible notes
Net cash provided by (used in) financing activities
Net increase (decrease) in cash, cash equivalents, and restricted cash

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Cytokinetics Inc. net cash provided by (used in) operating activities increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Cytokinetics Inc. net cash (used in) provided by investing activities decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Cytokinetics Inc. net cash provided by (used in) financing activities increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.